Infinity Pharmaceuticals Inc. (INFI) Reports Updated Phase 1 Data Showing Encouraging Clinical Activity Of IPI-145 In Chronic Lymphocytic Leukemia And T-Cell Lymphoma At American Society of Hematology Annual Meeting
12/9/2013 9:41:46 AM
NEW ORLEANS--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) today announced updated data from a Phase 1 study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with chronic lymphocytic leukemia (CLL), a potentially fatal hematologic malignancy (blood cancer). Data from the study showed that IPI-145 was highly active in patients with relapsed/refractory CLL, with a nodal response rate of 89 percent and an overall response rate of 48 percent as defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria1, including one complete response and 12 partial responses, among patients receiving IPI-145 at doses = 25 mg twice daily (BID). Onset of activity was rapid, with the majority of responses occurring in less than two months. These data, along with safety data showing that IPI-145 was generally well tolerated, support DUO, Infinity’s Phase 3 registration study of IPI-145 in patients with relapsed/refractory CLL, which is now enrolling patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by